<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00612196</url>
  </required_header>
  <id_info>
    <org_study_id>TB-402-001</org_study_id>
    <nct_id>NCT00612196</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male Volunteers</brief_title>
  <official_title>A Randomised, Phase I, Single Dose, Placebo-Controlled, Dose Escalation Study of TB-402, A Monocloncal Antibody Directed Against FACTOR VIII, Administered Intravenously in Healthy Male Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ThromboGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioInvent International AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ThromboGenics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dose escalation study to assess the safety and tolerability of TB-402, a monoclonal antibody
      directed against FVIII, versus placebo in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TB-402</intervention_name>
    <description>Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <arm_group_label>7</arm_group_label>
    <arm_group_label>8</arm_group_label>
    <arm_group_label>9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>10</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males 18 to 45 (Groups 1-9) or 55 to 75 (Group 10) years of age

          -  No clinically important abnormal physical, laboratory, ECG findings

          -  Normal (or abnormal but ncs) supine blood pressure (BP) and heart rate (HR)

        Exclusion Criteria:

          -  Self or family history of cardiovascular or pulmonary disorder, coagulation or
             bleeding disorders or reasonable suspicion of vascular malformations eg cerebral
             haemorrhage, aneurysm or premature stroke.

          -  Any autoimmune disease.

          -  Previous allergic reaction to immunoglobulin.

          -  Present, or history of, severe allergy, for example asthma or anaphylactic reactions
             or allergy requiring treatment.

          -  Consumption of aspirin, other non-steroidal anti-inflammatory drugs or other drugs
             known to affect platelet function or any other aspect of coagulation within 14 days
             before drug administration.

          -  Abnormal platelet function or clinically significant out of range values for any
             coagulation tests.

          -  History of important bleeding episodes eg haematemesis, rectal bleeding, severe or
             recurrent epistaxis, haemoptysis, haematuria or intracranial haemorrhage.

          -  Screening FVIII:C &lt; 50%.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas J Jensen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cyncron Clinical Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cyncron Clinical Research Unit</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2008</study_first_submitted>
  <study_first_submitted_qc>February 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2008</study_first_posted>
  <last_update_submitted>April 4, 2014</last_update_submitted>
  <last_update_submitted_qc>April 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2014</last_update_posted>
  <responsible_party>
    <name_title>Geraldine Cahillane</name_title>
    <organization>ThromboGenics Ltd.</organization>
  </responsible_party>
  <keyword>Safety and tolerability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

